WO2006122777A3 - Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln - Google Patents

Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln Download PDF

Info

Publication number
WO2006122777A3
WO2006122777A3 PCT/EP2006/004666 EP2006004666W WO2006122777A3 WO 2006122777 A3 WO2006122777 A3 WO 2006122777A3 EP 2006004666 W EP2006004666 W EP 2006004666W WO 2006122777 A3 WO2006122777 A3 WO 2006122777A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
derivatives
disubstituted thiazol
thiazol
disubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/004666
Other languages
English (en)
French (fr)
Other versions
WO2006122777A2 (de
Inventor
Robert Frank
Achim Kless
Ruth Jostock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to CA002609002A priority Critical patent/CA2609002A1/en
Priority to US11/915,156 priority patent/US20090215758A1/en
Priority to ES06753682T priority patent/ES2402200T3/es
Priority to PL06753682T priority patent/PL1890695T3/pl
Priority to JP2008511622A priority patent/JP5421589B2/ja
Priority to EP06753682A priority patent/EP1890695B1/de
Publication of WO2006122777A2 publication Critical patent/WO2006122777A2/de
Publication of WO2006122777A3 publication Critical patent/WO2006122777A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft 2,5-disubstituierte Thiazol-4-on-Derivate und deren Verwendung zur Herstellung von Arzneimitteln, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen.
PCT/EP2006/004666 2005-05-20 2006-05-17 Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln Ceased WO2006122777A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002609002A CA2609002A1 (en) 2005-05-20 2006-05-17 Use of 2,5-disubstituted thiazol-4-one derivatives in the production of drugs for the treatment of disorders or diseases which are mediated at least partly by vanilloid receptors 1(vr1/trpv1 receptors)
US11/915,156 US20090215758A1 (en) 2005-05-20 2006-05-17 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs
ES06753682T ES2402200T3 (es) 2005-05-20 2006-05-17 Utilización de derivados de tiazol-4-ona 2,5-disustituidos en medicamentos
PL06753682T PL1890695T3 (pl) 2005-05-20 2006-05-17 Zastosowanie 2,5-dipodstawionych pochodnych tiazol-4-onu w lekach
JP2008511622A JP5421589B2 (ja) 2005-05-20 2006-05-17 医薬への２，５−ジ置換されたチアゾール−４−オン誘導体の使用
EP06753682A EP1890695B1 (de) 2005-05-20 2006-05-17 Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005024012A DE102005024012A1 (de) 2005-05-20 2005-05-20 Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
DE102005024012.7 2005-05-20

Publications (2)

Publication Number Publication Date
WO2006122777A2 WO2006122777A2 (de) 2006-11-23
WO2006122777A3 true WO2006122777A3 (de) 2007-02-22

Family

ID=36997851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004666 Ceased WO2006122777A2 (de) 2005-05-20 2006-05-17 Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln

Country Status (8)

Country Link
US (1) US20090215758A1 (de)
EP (1) EP1890695B1 (de)
JP (1) JP5421589B2 (de)
CA (1) CA2609002A1 (de)
DE (1) DE102005024012A1 (de)
ES (1) ES2402200T3 (de)
PL (1) PL1890695T3 (de)
WO (1) WO2006122777A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2934104B2 (ja) 1992-08-19 1999-08-16 ファナック株式会社 プレス間ワーク搬送装置
DE102007040336A1 (de) * 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
CL2009000294A1 (es) * 2008-02-08 2009-10-23 Shlorion Pharma Inc Compuestos derivados de heterociclos aril metilideno; composicion farmaceutica que los comprende; y uso en el tratamiento del dolor neuropatico e inflamacion.
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (de) 2010-02-02 2014-10-15 Novartis AG Cyclohexylamidderivate als crf-rezeptorantagonisten
CN107249583B (zh) 2015-02-09 2021-05-07 国立大学法人冈山大学 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂
WO2021028518A1 (de) * 2019-08-15 2021-02-18 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-onen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1770583A1 (de) * 1967-06-06 1972-01-13 Clin Byla Ets Thiazolderivate und ihre Herstellung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP3884096B2 (ja) * 1995-10-13 2007-02-21 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
SE9701304D0 (sv) * 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
HUP0104204A3 (en) * 1998-11-03 2002-06-28 Glaxo Group Ltd Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof
WO2003057166A2 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
US7265138B2 (en) * 2003-02-10 2007-09-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20090156644A1 (en) * 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1770583A1 (de) * 1967-06-06 1972-01-13 Clin Byla Ets Thiazolderivate und ihre Herstellung

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
AKERBLOM E B: "Synthesis and structure-activity relationships of a series of antibacterially active 5-(5-nitro-2-furfurylidene)thiazolones, 5-(5-nitro-2-furylpropenylidene) thiazolones, and 6-(5-nitro-2-furyl)-4H- 1,3-thiazinones", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 17, no. 6, June 1974 (1974-06-01), pages 609 - 615, XP002272538, ISSN: 0022-2623 *
APPENDINO G ET AL: "TRPV1 (VANILLOID RECEPTOR, CAPSAICIN RECEPTOR) AGONISTS AND ANTAGONISTS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 13, no. 12, 2003, pages 1825 - 1837, XP002320750, ISSN: 1354-3776 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1967, BESYADETS'KA, O. I.: "Synthesis of 5-substituted 2-piperidino-2-thiazolin-4-ones", XP002403441, retrieved from STN Database accession no. 1967:482152 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002, ZIMENKOVSKY, B. S. ET AL: "Study of trends in interaction between structure and biological activity among thiazolidine derivatives", XP002403429, retrieved from STN Database accession no. 2003:170522 *
DATABASE REGISTRY STN; 13 November 2000 (2000-11-13), XP002403431 *
DATABASE REGISTRY STN; 16 January 2001 (2001-01-16), XP002403430 *
DATABASE REGISTRY STN; 20 December 2001 (2001-12-20), XP002403435 *
DATABASE REGISTRY STN; 20 March 2003 (2003-03-20), XP002403436 *
DATABASE REGISTRY STN; 21 October 2002 (2002-10-21), XP002403434 *
DATABASE REGISTRY STN; 28 December 2000 (2000-12-28), XP002403433 *
DATABASE REGISTRY STN; 31 October 2000 (2000-10-31), XP002403432 *
DATABASE REGISTRY STN; 31 October 2000 (2000-10-31), XP002403437 *
DATABASE REGISTRY STN; 31 October 2000 (2000-10-31), XP002403438 *
DATABASE REGISTRY STN; 31 October 2000 (2000-10-31), XP002403439 *
DATABASE REGISTRY STN; 31 October 2000 (2000-10-31), XP002403440 *
FARMATSEVTICHNII ZHURNAL (KIEV) , 22(1), 9-11 CODEN: FRZKAP; ISSN: 0367-3057, 1967 *
FIZIOLOGICHNO AKTIVNI RECHOVINI , (2), 58-64 CODEN: FARICW, 2002 *
HOLZER ET AL: "TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 500, no. 1-3, 1 October 2004 (2004-10-01), pages 231 - 241, XP005480419, ISSN: 0014-2999 *
SONG YUNTAO ET AL: "Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 7, 8 April 1999 (1999-04-08), pages 1151 - 1160, XP002400520, ISSN: 0022-2623 *
SZALLASI ARPAD ET AL: "Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?", JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, no. 11, 20 May 2004 (2004-05-20), pages 2717 - 2723, XP002400521, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
US20090215758A1 (en) 2009-08-27
JP2008540595A (ja) 2008-11-20
ES2402200T3 (es) 2013-04-29
DE102005024012A1 (de) 2006-11-23
JP5421589B2 (ja) 2014-02-19
EP1890695B1 (de) 2013-02-20
WO2006122777A2 (de) 2006-11-23
EP1890695A2 (de) 2008-02-27
PL1890695T3 (pl) 2013-05-31
CA2609002A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2007045462A3 (de) Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
EP1740156B8 (de) Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform
PL1673352T3 (pl) Sulfoksyiminopodstawione pirymidyny jako inhibitory CDK i/lub VEGF, ich wytwarzanie i zastosowanie jako środków leczniczych
HUS1400056I1 (hu) Glükopiranozil-helyettesített benzol-származékok, az említett vegyületeket tartalmazó gyógyszerek, azok alkalmazása, és eljárás elõállításukra
WO2007025540A3 (de) Substituierte imidazo[1,2b]pyridazine als kinase-inhibitoren, deren herstellung und verwendung als arzneimittel
IL181012A0 (en) Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
IL188606A0 (en) Novel 1,4-benzothiazepine-1,1-dioxide, derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
WO2007000325A3 (de) Substituierte 1-oxa-3,8-diazaspiro[4.5]-decan-2-on-verbindungen und deren verwendung zur herstellung von arzneimitteln
IL179758A (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
WO2006018184A3 (de) Spirocyclische cyclohexan-derivate
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2007104485A3 (de) Substituierte imidazo[2,1-b]thiazol-verbindungen und ihre verwendung zur herstellung von arzneimitteln
WO2006122777A3 (de) Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
WO2004022542A3 (de) Substituierte 1,2,3,4-tetrahydrochinolinderivate
WO2006122769A3 (de) Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz
WO2008030840A3 (en) Synthesis of sphingosines and their derivatives
WO2007057316A3 (en) Novel process for the preparation of thoc
IL186457A0 (en) Process for the preparation of 9,10-dehydro-12,13-desoxyepothilone derivatives
WO2004092736A3 (en) Derivatives of azithromycin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006753682

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2609002

Country of ref document: CA

Ref document number: 2008511622

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006753682

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11915156

Country of ref document: US

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)